You are here
Avanafil 2.00: The 2nd generation of PDE5-Is has begun
Chair: Vincenzo G. Mirone, Naples, Italy
Erectile dysfunction, a highly prevalent cause of sexual dysfunction in men, is effectively treated with a phosphodiesterase type 5 (PDE5) inhibitor in most cases. However, in a non-negligible number of cases, the patient or partner’s sexual dissatisfaction with the treatment results in discontinuation. A second-generation PDE5 inhibitor, Avanafil, was developed to address this deficiency and was recently approved in the EU. Clinical results have shown that Avanafil is a better tolerated treatment, even at the highest dosage, with rapid and sustained efficacy. Thus Avanafil provides an innovative, on-demand solution for erectile dysfunction, allowing patients to respond immediately to their partner’s wishes and obviating the need to plan sex in advance.
Industry session sponsored by The Menarini Group Sunday 13 March 2016
Prostate cancer management – Selecting the right treatment for the right patient
Chair: F. Montorsi, Milan, Italy
The aims and objectives of this session are to review current best practice in prostate cancer management through presentation and discussion of case reports from patients with prostate cancer, highlighting the heterogeneity in comorbidities, side-effects experienced, and treatment options available; to discuss the risk/benefit ratio of treatments from an individual perspective and on the basis of patients’ clinical characteristics and risk factors; and to discuss ways in which patients can take control of their disease and treatment by applying lifestyle changes to manage their prostate cancer and the side-effects of treatment.
Industry session sponsored by Ferring, Sunday 13 March 2016